Proteasome inhibition induces both antioxidant and hb f responses in sickle cell disease via the nrf2 pathway

Hemoglobin

Volumn 38, Issue 3, 2014, Pages 188-195

  Pullarkat, Vinod ^a,d   Meng, Zhuo ^a   Tahara, Stanley M ^b   Johnson, Cage S ^a   Kalra, Vijay K ^c  

^a Jane Anne Nohl Division of Hematology   (United States)

^b Department of Molecular Microbiology and Immunology ^*  (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Antioxidant response; Hb F; Nuclear factor (erythroid derived 2) like 2 (NFE2L2 of Nrf2); Proteasome inhibitors; Reactive oxygen species (ROS); Sickle cell disease

Indexed keywords

ANTIOXIDANT; BORTEZOMIB; GLUTATHIONE; HEMOGLOBIN F; IMMUNOGLOBULIN; IXAZOMIB CITRATE; PROTEASOME; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR NRF2; ANTINEOPLASTIC AGENT; ATP DEPENDENT 26S PROTEASE; BORONIC ACID DERIVATIVE; NFE2L2 PROTEIN, HUMAN; PROTEASOME INHIBITOR; PYRAZINE DERIVATIVE;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; SICKLE CELL ANEMIA; ACTIVE TRANSPORT; ANEMIA, SICKLE CELL; CELL NUCLEUS; CLINICAL TRIAL; DRUG EFFECTS; ERYTHROID PRECURSOR CELL; FEMALE; GENETIC TRANSCRIPTION; GENETICS; K562 CELL LINE; MALE; METABOLISM; PATHOLOGY;

ACTIVE TRANSPORT, CELL NUCLEUS; ANEMIA, SICKLE CELL; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CELL NUCLEUS; ERYTHROID PRECURSOR CELLS; FEMALE; FETAL HEMOGLOBIN; HUMANS; K562 CELLS; MALE; NF-E2-RELATED FACTOR 2; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PYRAZINES; REACTIVE OXYGEN SPECIES; TRANSCRIPTION, GENETIC;

EID: 84900468337     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.3109/03630269.2014.898651     Document Type: Article

References (32)

1. Nur E, Biemond BJ, Otten H-MB, et al. Oxidative stress in sickle cell disease: Pathophysiology and potential implications for disease management. Am J Hematol. 2011;86(6):484-489.
2. Kato GJ, Hebbel RP, Steinberg MH, Gladwin MT. Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine and new research directions. Am J Hematol. 2009; 84(9):618-625.
3. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet. 2010;376(9757):2018-2031.
4. Wood KC, Hebbel RP, Granger DN. Endothelial cell NADPH oxidase mediates the cerebral microvascular dysfunction in sickle cell transgenic mice. FASEB J. 2005;19(8):989-991.
5. Kaul DK, Liu XD, Choong S, et al. Anti-inflammatory therapy ameliorates leukocyte adhesion and microvascular flow abnormalities in transgenic sickle mice. Am J Physiol Heart Circ Physiol. 2004;287(1):H293-H301.
6. Hur W, Gray NS. Small molecule modulators of antioxidant response pathway. Curr Opin Chem Biol. 2011;15(1):162-173.
7. Baird L, Dinkova-Kostova AT. The cytoprotective role of the Keap1-Nrf2 pathway. Arch Toxicol. 2011;85(4):241-272.
8. Villeneuve NF, Lau A, Zhang DD. Regulation of the Nrf2-Keap1 antioxidant response by the ubiquitin proteasome system: An insight into cullin-ring ubiquitin ligases. Antioxid Redox Signal. 2010;13(11):1699-1712.
9. Macari ER, Lowrey CH. Induction of human fetal hemoglobin via the NRF2 antioxidant response signaling pathway. Blood. 2011; 117(22):5987-5997.
10. Akinsheye I, Alsultan A, Solovieff N, et al. Fetal hemoglobin in sickle cell anemia. Blood. 2011;118(1):19-27.
11. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330(23):1639-1644.
12. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med. 1991;325(1):11-16.
13. Risso A, Fabbro D, Damante G, Antonutto G. Expression of fetal hemoglobin in adult humans exposed to high altitude hypoxia. Blood Cells Molec Dis. 2012;48(3):147-153.
14. Yang YM, Pace B, Kitchens D, et al. BFU-E colony growth in response to hydroxyurea: Correlation between in vitro and in vivo fetal hemoglobin induction. Am J Hematol. 1997;56(4):252-258.
15. Ho JA, Pickens CV, Gamscik MP, et al. In vitro induction of fetal hemoglobin in human erythroid progenitor cells. Exp Hematol. 2003;31(7):586-591.
16. Reece DE, Sullivan D, Lonial S, et al. Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma. Cancer Chemother Pharmacol. 2011;67(1):57-67.
17. Sekhar KR, Soltanninassab SR, Borrelli MJ, et al. Inhibition of the 26S proteasome induces expression of GLCLC, the catalytic subunit for gamma-glutamylcysteine synthetase. Biochem Biophys Res Commun. 2000;270(1):311-317.
18. Stewart D, Killeen E, Naquin R, et al. Degradation of transcription factor Nrf2 via the ubiquitin-proteasome pathway and stabilization by cadmium. J Biol Chem. 2003; 278(4):2396-2402.
19. Xia L, Pan J, Yao L, McEver RP. A proteasome inhibitor, an antioxidant or a salicylate, but not a glucocorticoid blocks constitutive and cytokine-inducible expression of P-selectin in human endothelial cells. Blood. 1998;91(5):1625-1632.
20. Lalu MM, Xu H, Sankaralingam S, Davidge ST. Proteasome inhibition decreases inflammation in human endothelial cells exposed to liposaccharide. J Cardiovasc Pharmacol. 2012; 60(4):381-389.
21. Bauer DE, Kamran SC, Orkin SH. Reawakening fetal hemoglobin: Prospects for new therapies for the b-globin disorders. Blood. 2012; 120(15):2945-2953.
22. Sankaran VG, Nathan DG. Reversing the hemoglobin switch. N Engl J Med. 2010;363(23):2258-2260.
23. Forget BG. Progress in understanding the hemoglobin switch. N Engl J Med. 2011;365(9):852-854.
24. Ware RE, Despotovic JM, Mortier NA, et al. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood. 2011; 118(18):4985-4991.
25. Lebensburger JD, Pestina TI, Ware RE, et al. Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model. Haematologica. 2010;95(9):1599-1603.
26. Steinberg MH, Lu Z-H, Barton FB, et al. Fetal hemoglobin in sickle cell anemia: Determinants of response to hydroxyurea. Blood. 1997;89(3):1078-1088.
27. Chandra J. Oxidative stress by targeted agents promotes cytotoxicity in hematologic malignancies. Antioxid Redox Signal. 2009; 11(5):1123-1137.
28. Mullard A. Next-generation proteasome blockers promise safer cancer therapy. Nat Med. 2012;18(1):7. doi:10.1038/nm0112-7a.
29. Dick LR, Fleming PE. Building on bortezomib: Second generation proteasome inhibitors as anti-cancer therapy. Drug Discov Today. 2010;15(5-6):243-249.
30. Vij R, Siegel DS, Jagannath S, et al. An open-label, singlearm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol. 2012; 158(6):739-748.
31. Kupperman E, Lee EC, Cao Y, et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 2010;70(5):1970- 1980.
32. Chauhan D, Tian Z, Zhou B, et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res. 2011;17(16):5311-5532.